Med Spa Regulatory News & Headlines

The fast-moving federal and state developments shaping med spa compliance right now. Updated regularly.
✓ Reviewed by legal counsel | Last reviewed: August 11, 2026

Med spa regulation is changing faster in 2026 than at any point in the industry's history. GLP-1 compounding, telemedicine prescribing, peptides, and ozone therapy are all under active federal and state scrutiny. This page tracks the developments that matter, with links to the primary sources so you can read the facts yourself. For your state's specific rules, use the state selector below.

More states added regularly. Don't see yours? Check your eligibility — we're licensed in all 50 states.

The Headlines Right Now

GLP-1 compounding: the shortage loophole is closed, and enforcement is escalating

The compounded GLP-1 era that built half the weight-loss programs in America is over. The FDA declared the tirzepatide shortage resolved in October 2024 and semaglutide in February 2025. Once a drug leaves the shortage list, the "essentially-a-copy" rule under Section 503A of the Food, Drug, and Cosmetic Act kicks back in, making most bulk-compounded semaglutide and tirzepatide illegal outside narrow, documented clinical need. Med spas still prescribing on 2024 habits are exposed.

Read: FDA drug shortage and compounding guidance — fda.gov/drugs

FDA hits telehealth companies with a fresh wave of warning letters

During the week of June 15, 2026, the FDA issued 25 warning letters to telehealth companies over allegedly false or misleading promotional claims about compounded GLP-1 products, which the agency views as misbranding under the Federal Food, Drug, and Cosmetic Act. This followed 30 warning letters to telehealth companies in March 2026. The message to any practice marketing compounded GLP-1: promotional claims are being read closely.

Read: FDA warning letters — fda.gov/warning-letters

DEA telemedicine prescribing flexibilities expire December 31, 2026

The pandemic-era DEA flexibilities that let providers prescribe controlled substances via synchronous audio-video without a prior in-person visit have been extended through December 31, 2026, but permanent rules are expected before then. Any med spa relying on remote controlled-substance prescribing should watch this deadline closely; the rules that replace the flexibilities may look very different. (Note: GLP-1 medications are not controlled substances and do not require DEA registration to prescribe, but many practices offer other services that do.)

Read: DEA telemedicine — dea.gov

GLP-1 litigation crosses 4,400 filed lawsuits

As of early 2026, more than 4,400 GLP-1 lawsuits had been filed, most consolidated into federal multidistrict litigation. Drug manufacturers have separately sued telehealth companies, med spas, and compounding pharmacies over unapproved or counterfeit compounded semaglutide, and poison-control calls for GLP-1 dosing errors have risen sharply, many tied to compounded vials requiring patients to self-measure doses. This is the fastest-growing liability exposure in the industry.

Read: Endocrinology Advisor (GLP-1 litigation overview) — read the overview

Peptides: a regulatory gray zone under growing scrutiny

Many peptides marketed in wellness and aesthetic settings are not FDA-approved, and several appear on the FDA's lists of substances that raise compounding concerns. Practices offering peptide therapy should treat this as an active-risk area and confirm sourcing and prescribing align with current FDA and state pharmacy board positions. State positions vary; check your state guide.

Read: FDA compounding — fda.gov/human-drug-compounding

Ozone therapy: FDA's stated position is unchanged

The FDA contin